Gluetacs Therapeutics (Shanghai) Co. Ltd. has synthesized molecular glue degraders comprising a cereblon (CRBN) binding moiety acting as protein degradation inducers reported to be useful for the treatment of anemia, cancer, diabetes, infections, transplant rejection, inflammation, autoimmune and sarcoidosis, among others.